Shu Kurosaki

Shu Kurosaki, CPA, is the President of Kurobei, Inc. since July 2018, providing finance and accounting consultancy to VC-backed early-stage life science companies. Additionally, Shu serves as the Consulting Head of Finance for several companies including Electra Therapeutics, Perfuse Therapeutics, and Leal Therapeutics, where involvement commenced at inception. As Chief Financial Officer for Synchronicity Pharma, Shu has been engaged since the company's early stages. Further consultancy roles include Enliven Therapeutics, a publicly traded company developing precision oncology medicine, and Novome Biotechnologies, focusing on genetically engineered medicines. Past experience includes being the Chief Financial Officer at Reset Therapeutics and Vice President of Finance & Administration at Digital Air Strike. Shu holds a BS in Business with an emphasis on accounting and marketing from the University of California, Berkeley.